Critical Care Medicine, Год журнала: 2024, Номер 53(1), С. e186 - e189
Опубликована: Дек. 3, 2024
Язык: Английский
Bioorganic & Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 118092 - 118092
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown
Опубликована: Март 18, 2025
Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help
Язык: Английский
Процитировано
0
BMC Pulmonary Medicine, Год журнала: 2025, Номер 25(1)
Опубликована: Май 8, 2025
The optimal duration of steroid therapy for patients with COVID-19 remains unclear. This study compared clinical outcomes between early withdrawal (EW; ≤10 days) and prolonged tapering (PT; >10 in severe requiring oxygen support. retrospective, single-center cohort included adult WHO-CPS scores 6-9 admitted to a tertiary hospital Seoul, Republic Korea. After 1:1 propensity score matching, 68 were each group. Primary 28-day 60-day mortality. Secondary aggravation, rebound pneumonia, infectious complications, readmission or emergency department (ED) revisits, support, lengths hospitalization ICU stay. Baseline characteristics well balanced after matching. No significant differences observed mortality (5.9% vs. 10.3%, HR 0.54, 95% CI 0.16-1.84, p = 0.32) (14.7% 11.8%, 1.22, 0.48-3.10, 0.67) PT EW groups. Rates ED revisit also comparable. However, the group had significantly longer durations support (17.5 13.0 days, 0.001), (20.0 14.0 stay (5.0 1.0 0.01). Prolonged beyond 10 days did not improve survival other COVID-19, suggesting that may be appropriate selected patients.
Язык: Английский
Процитировано
0
Clinical Infectious Diseases, Год журнала: 2024, Номер 80(1), С. 72 - 73
Опубликована: Сен. 20, 2024
Язык: Английский
Процитировано
0
Critical Care Medicine, Год журнала: 2024, Номер 53(1), С. e186 - e189
Опубликована: Дек. 3, 2024
Язык: Английский
Процитировано
0